Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Sha Tin, Hong Kong.
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong Cancer Institute, Sha Tin, Hong Kong ; State Key Laboratory of South China, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Sha Tin, Hong Kong.
Onco Targets Ther. 2014 Oct 4;7:1817-28. doi: 10.2147/OTT.S48409. eCollection 2014.
Colorectal cancer is the second most common cancer in Hong Kong and its incidence is rising in economically developed Chinese cities, including Hong Kong and Shanghai. Several studies conducted in the People's Republic of China have characterized the unique molecular epidemiology of familial colorectal cancer syndromes and molecular biomarkers such as microsatellite instability and genetic mutations (eg, KRAS, NRAS, BRAF, PIK3CA, ERCC1) in Chinese populations. Interethnic differences in anticancer drug response and toxicity have been well described in many cancers, and this review examined the literature with regard to the tolerance of Chinese patients to commonly used chemotherapeutic regimens and targeted therapies for metastatic colorectal cancer. Studies on the pharmacogenomic differences in drug metabolizing and DNA repair enzymes between Chinese, North Asians, and Caucasian patients were also reviewed.
结直肠癌是香港第二常见的癌症，其发病率在包括香港和上海在内的经济发达的中国城市中呈上升趋势。在中国进行的几项研究描述了家族性结直肠癌综合征的独特分子流行病学特征以及分子生物标志物，如微卫星不稳定性和基因突变（如 KRAS、NRAS、BRAF、PIK3CA、ERCC1）在中国人中的特征。在许多癌症中，抗癌药物反应和毒性的种间差异已经得到了很好的描述，本综述检查了有关中国患者对转移性结直肠癌常用化疗方案和靶向治疗的耐受性的文献。还对中、北亚和高加索患者在药物代谢和 DNA 修复酶方面的药物基因组学差异进行了研究。
